ClinicalTrials.gg
CompletedNCT01642485C11035Updated Aug 20, 2014Results posted

Food and Insulin Effect on QT/QTC Interval of ECG

A Phase 1 interventional study of Moxifloxacin 400 mg fasted and FDA breakfast in Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use and C-Peptide Effects on the QT/QTc Interval, sponsored by Richmond Pharmacology Limited. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-20.

Sponsored by Richmond Pharmacology Limited · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 105 studies in Insulin Resistance with a site in United Kingdom — 6 open to participants now, 8 under way, none of them phase 3. Insulin Resistance · United Kingdom.

Enrollment
44th of 95
32 · median 31
Started
2011
with 8 others
Phase 1
5 of 105
none open now
Registered
33rd of 105
by date

Among the 105 studies in Insulin Resistance with a site in United Kingdom, this one is the 44th largest by enrollment of the 95 interventional ones that give a count, is one of 9 that started in 2011, is one of 5 in phase 1, and was the 33rd registered.

Insulin Resistance

2,972 studies on the registry are indexed under Insulin Resistance; 337 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

6 of the 105 studies in Insulin Resistance with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Insulin Resistance with a site in United Kingdom, or all of them as a file.
02

Study summary

Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or pharmacodynamics (PD) of the study drug. However, there is no published data clarifying this issue. There is also a paucity of data investigating ethnic differences of the effects of medicines on QTc.

The aims of the study were to compare the effect of different food contents to placebo on the changes in ECG and to demonstrate the effect of insulin, C-peptide and glucose on the ECG. This was done by giving different treatments on separate days, which included intravenous insulin, a high carbohydrate breakfast [>70%], and a calorie reduced low carbohydrate American FDA standard breakfast. Moxifloxacin 400 mg was used as a positive control and was given with and without food to Caucasian and Japanese volunteers to investigate racial differences.

Read the detailed description

This study was initially performed in 24 healthy Caucasian and Japanese volunteers with an option to increase the sample size to up to 54 volunteers. The decision to increase the sample size to 32 was based on the standard deviation of the ECG intervals observed in the first 24 volunteers. This analysis was performed by an independent statistician under blinded conditions.

Each volunteer participated in 2 periods. Each period consisted of 1 baseline day (D-1) followed by 3 study days (D1 - D3) when the various food effect and drug treatments or placebo were administered. All volunteers received all treatments. Moxifloxacin was always given on D3 to prevent any carryover effect and there was a minimum washout period of 3 days in between the 2 periods.

How well the treatments (insulin/glucose, high carbohydrate breakfast, calorie reduced breakfast and moxifloxacin) were tolerated by the volunteers was assessed and any side effects noted.

We compared the effects of the various treatments between Caucasian and Japanese volunteers.

Moxifloxacin and placebo were given to volunteers by mouth, i.e. they were asked to swallow them with water. The different types of breakfast were provided which volunteers were asked to eat. Insulin and glucose were administered intravenously (Insulin/glucose clamp). Hence, the study was performed as an open-label design.

This study was conducted as a single site study at Richmond Pharmacology/ St George's University of London.

03

Conditions studied

  • Effects of Different Meals on the QT/QTc Interval
  • Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use
  • C-Peptide Effects on the QT/QTc Interval
  • Moxifloxacin ECG Profile in Fed and Fasted State
  • Japanese vs. Caucasian TQT Comparison

Keywords

  • Insulin clamp
  • Glucose clamp
  • Moxifloxacin
  • Fed
  • Fasted
  • QT/QTC interval
  • TQT
  • ECG
  • Meal effects
  • C Peptide
  • Japanese Caucasian bridging
  • TQT bridging
  • FDA standard breakfast
  • Adaptive study design
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female, 20 - 45 years old
  2. Signed ICF
  3. Japanese - a descendant of four Japanese grandparents, carrying a Japanese passport and has not been outside Japan for more than 5 years prior to screening
  4. The Caucasian - light to brown skin pigmentation; straight to wavy or curly hair; indigenous to Europe, northern Africa, western Asia, and India. The study may also include Caucasians from North America, Australia and South Africa
  5. No clinical findings on the physical examination
  6. (BMI) = 18 - 25 kg/m2, body weight at least 48 kg.
  7. Systolic blood pressure 90-145 mmHg, diastolic blood pressure 40-90 mmHg, and heart rate 40-90 bpm
  8. Triplicate 12 lead without abnormalities
  9. 24 hour 12 lead Holter ECG without clinically relevant abnormalities
  10. Haematology, biochemistry and urinalysis within the normal range
  11. Must agree to use acceptable methods of

Exclusion criteria

Exclusion Criteria:

  1. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug
  2. History of syncope.
  3. Family history of sudden death.
  4. Family history of premature cardiovascular death.
  5. Family history of congenital long syndrome or Brugada's syndrome.
  6. History of arrhythmias and ischemic heart disease
  7. Conditions predisposing to electrolyte imbalances (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).
  8. Abnormal in the standard 12-lead ECG and 24-hour 12 lead Holter ECG
  9. Abnormal rhythm, conduction or morphology of resting ECG, such as:

    • Sinus node dysfunction.
    • Clinically significant PR (PQ) interval prolongation.
    • Intermittent second or third degree AV block.
    • Incomplete or complete bundle branch block.
    • Abnormal T wave morphology.
    • Prolonged QTcB >450 msec or shortened QTcB \< 350 msec or family history of long QT syndrome.
  10. Abnormal blood glucose result (blood glucose >7.8mmol/l)
  11. Significant family history of diabetes mellitus.
  12. Significantly elevated fasting blood glucose level
  13. Signs and/or symptoms of acute illness in the four-week period prior to screening.
  14. Veins unsuitable for intravenous puncture or cannulation on either arm
  15. Known to any medicines administered in the trial.
  16. Treatment with any prescribed medication during the 2 weeks prior to first baseline day.
  17. Treatment with any over-the-counter (OTC) medications during the 2 weeks prior to first baseline day.
  18. Treatment with vitamins and/or minerals within 48 hours prior to the first baseline day.
  19. Treatment with another drug within 4 weeks prior to dosing or having participated in more than 3 investigational drug studies within a year prior to dosing.
  20. Positive urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates and methadone) or the alcohol breath test
  21. History or clinical evidence of alcoholism (regular weekly alcohol intake of more than 14 units if female and 21 units if male) or drug abuse (compulsive, repetitive and/or chronic use of drugs or other substances with or without problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms)
  22. Excessive caffeine consumption (≥800 mg per day)
  23. Smoking within 3 months prior to screening
  24. Loss of 250 mL or more blood within 3 months prior to screening.
  25. Positive results from the hepatitis serology, except for vaccinated subjects.
  26. Positive results from the serology.
  27. Any circumstances or conditions, which may affect full participation in the study or compliance with the protocol.
  28. Legal incapacity or limited legal capacity.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Moxifloxacin 400 mg fasted

    Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.

    Drug: Moxifloxacin 400 mg fasted · Other: FDA breakfast · Other: Continental breakfast · Procedure: Insulin Clamp · Drug: Placebo

  • Experimental
    Moxifloxacin 400 mg fed

    Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.

    Other: FDA breakfast · Other: Continental breakfast · Drug: Moxifloxacin 400 mg fed · Procedure: Insulin Clamp · Drug: Placebo

Interventions

  • Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours. This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies.

    Also known as: Moxifloxacin

  • OtherFDA breakfast

    Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.

  • OtherContinental breakfast

    High carbohydrate breakfast (\>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.

  • Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.

    Also known as: Moxifloxacin

  • ProcedureInsulin Clamp

    A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.

  • DrugPlacebo

    Comparison of different meals effect on Moxifloxacin PK profile

06

What researchers measure

Primary outcomes

  1. The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin

    The primary baseline corrections were calculated using averaged QTc baseline values (the mean of all median readings recorded for each time-point on the baseline Day -1). This single value (QTcbaselineAV) was used to calculate ΔQTc for each study period.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose

Secondary outcomes

  1. The Food Effects (Calorie Reduced FDA Breakfast and Carbohydrate Rich Continental Style) on QTcF

    Scott et al (2002) demonstrated an increase in the heart rate of 10bpm in some healthy subjects following ingestion of a carbohydrate meal. There was significant correlation between the resultant hyperinsulinaemia and an increase in skeletal muscle blood flow, and sympathetic activity, with a reduction in vascular resistance. If postprandial insulinaemia is a significant influence on the QT interval, then carbohydrate rich meals would be expected to show greater effect. Therefore, to explore this on two separate days of the study subjects will be given one of two different types of breakfast: 1. A high carbohydrate content breakfast, (\>70% carbohydrate) 2. A reduced calorie FDA standard breakfast, (58% fat, low carbohydrate content) to determine effect on QT interval.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose

  2. Moxifloxacin 400 mg (Single Dose) Compared to Placebo on the Mean QT/QTc Interval.

    "Moxifloxacin 400mg Fasted" group is reporting the maximum change in QT/QTc interval from placebo treatment.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose

  3. Insulin, Glucose and C-Peptide Effects on the QT/QTc Interval

    The effect on QTc was investigated using linear mixed effect models with placebo corrected QTcF (change from average baseline) as a dependent variable and insulin, glucose and C-peptide (placebo corrected) as covariates for the data obtained under the euglycaemic clamp as well as for all data obtained under the clamp and the two types of breakfast.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose

  4. The QTcF Profile of Oral Moxifloxacin (400 mg) in Healthy Japanese Versus Caucasian Subjects

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose

07

Results

Posted Aug 20, 2014
Limitations and caveats
Our findings based on the confirmatory and concentration-effect analysis suggest that any difference between ethnicities was most likely attributable to differences in plasma concentrations and not differences in sensitivity to moxifloxacin.

Participant flow

Period 1, Day 1
Participant flow — Period 1, Day 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8
Started44444444
Completed44444444
Not completed00000000
Period 1, Day 2
Participant flow — Period 1, Day 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8
Started44444444
Completed44444444
Not completed00000000
Period 1, Day 3
Participant flow — Period 1, Day 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8
Started44444444
Completed44444444
Not completed00000000
Period 2, Day 1
Participant flow — Period 2, Day 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8
Started44444444
Completed44444444
Not completed00000000
Period 2, Day 2
Participant flow — Period 2, Day 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8
Started44444444
Completed44444444
Not completed00000000
Period 2, Day 3
Participant flow — Period 2, Day 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8
Started44444444
Completed44444444
Not completed00000000

Outcome measures

PrimaryThe Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin

The primary baseline corrections were calculated using averaged QTc baseline values (the mean of all median readings recorded for each time-point on the baseline Day -1). This single value (QTcbaselineAV) was used to calculate ΔQTc for each study period.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose
Reported as:
Mean · ms
The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin
msFasted GroupFed Group
The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin14.4 (11.9 to 16.8)11.6 (9.1 to 14.1)
Statistical analysis
  • Fasted Group · t-test, 1 sided · p = 0.05
SecondaryThe Food Effects (Calorie Reduced FDA Breakfast and Carbohydrate Rich Continental Style) on QTcF

Scott et al (2002) demonstrated an increase in the heart rate of 10bpm in some healthy subjects following ingestion of a carbohydrate meal. There was significant correlation between the resultant hyperinsulinaemia and an increase in skeletal muscle blood flow, and sympathetic activity, with a reduction in vascular resistance. If postprandial insulinaemia is a significant influence on the QT interval, then carbohydrate rich meals would be expected to show greater effect. Therefore, to explore this on two separate days of the study subjects will be given one of two different types of breakfast: 1. A high carbohydrate content breakfast, (\>70% carbohydrate) 2. A reduced calorie FDA standard breakfast, (58% fat, low carbohydrate content) to determine effect on QT interval.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose
Reported as:
Mean · ms
The Food Effects (Calorie Reduced FDA Breakfast and Carbohydrate Rich Continental Style) on QTcF
msFDA BreakfastContinental BreakfastPlacebo at Baseline
The Food Effects (Calorie Reduced FDA Breakfast and Carbohydrate Rich Continental Style) on QTcF-6.8 (-9.3 to -4.3)-7.9 (-10.4 to -5.5)412.4 (407.9 to 416.9)
Statistical analysis
  • FDA Breakfast vs Continental Breakfast · t-test, 1 sided · p = 0.05
  • Continental Breakfast · Mean difference (final values): -7.9 · 90% CI -10.4 to -5.5
  • FDA Breakfast · Median difference (final values): -6.8 · 90% CI -9.3 to -4.3
SecondaryMoxifloxacin 400 mg (Single Dose) Compared to Placebo on the Mean QT/QTc Interval.

"Moxifloxacin 400mg Fasted" group is reporting the maximum change in QT/QTc interval from placebo treatment.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose
Reported as:
Mean · ms
Moxifloxacin 400 mg (Single Dose) Compared to Placebo on the Mean QT/QTc Interval.
msMoxifloxacin 400 mg FastedPlacebo
Moxifloxacin 400 mg (Single Dose) Compared to Placebo on the Mean QT/QTc Interval.14.4 (11.9 to 16.8)414.2 (409.6 to 418.8)
SecondaryInsulin, Glucose and C-Peptide Effects on the QT/QTc Interval

The effect on QTc was investigated using linear mixed effect models with placebo corrected QTcF (change from average baseline) as a dependent variable and insulin, glucose and C-peptide (placebo corrected) as covariates for the data obtained under the euglycaemic clamp as well as for all data obtained under the clamp and the two types of breakfast.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose
Reported as:
Median · msec
Insulin, Glucose and C-Peptide Effects on the QT/QTc Interval
msecInsulin ClampGlucoseC-peptide
Insulin, Glucose and C-Peptide Effects on the QT/QTc Interval-0.01 (-0.02 to 0.04)-0.86 (-1.45 to -0.27)-0.71 (-0.98 to -0.45)
SecondaryThe QTcF Profile of Oral Moxifloxacin (400 mg) in Healthy Japanese Versus Caucasian Subjects
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4 and 6 hours post-dose
Reported as:
Mean · ms
The QTcF Profile of Oral Moxifloxacin (400 mg) in Healthy Japanese Versus Caucasian Subjects
msCaucasian Fasted GroupCaucasian Fed GroupJapanese Fasted GroupJapanese Fed Group
The QTcF Profile of Oral Moxifloxacin (400 mg) in Healthy Japanese Versus Caucasian Subjects9.0 (3.2 to 14.7)13.7 (8.2 to 19.2)17.3 (13.9 to 20.6)10.1 (5.1 to 15.1)

Adverse events

Collected over The AEs were recorded at screening: Days: -21 to -3, daily through Period 1 (from Day -2 to Day 3), washout period (3 days), daily through Period 2 (from Day -2 to Day 3) and at follow-up visit (7-14 days after the end of Period 2).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moxifloxacin 400 mg Fasted—0/32 (0%)0/32 (0%)
Moxifloxacin 400 mg Fed—0/32 (0%)0/32 (0%)

Baseline characteristics

The study population consisted of healthy non-smoking, subjects. Electrocardiograms in the placebo arm were recorded twice in fasted and fed condition.

Age, Continuous
Age, Continuous(years)All Study Participants
Caucasian25.6 ± 4.7
Japanese27.6 ± 3.3
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female14
Male18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Study Participants
Caucasian13
Japanese19
Region of Enrollment
Region of Enrollment(participants)All Study Participants
United Kingdom32
Body Mass Index
Body Mass Index(participants)All Study Participants
>18 kg/m^232
>25 kg/m^20
08

Study locations

1 site
  • Richmond Pharmacology Ltd
    London, Tooting SW17 0RE, United Kingdom
09

References and documents

Publications

  • Taubel J, Wong AH, Naseem A, Ferber G, Camm AJ. Shortening of the QT interval after food can be used to demonstrate assay sensitivity in thorough QT studies. J Clin Pharmacol. 2012 Oct;52(10):1558-65. doi: 10.1177/0091270011419851. Epub 2011 Nov 8. PubMed 22067197 ↗
  • Scott EM, Greenwood JP, Vacca G, Stoker JB, Gilbey SG, Mary DA. Carbohydrate ingestion, with transient endogenous insulinaemia, produces both sympathetic activation and vasodilatation in normal humans. Clin Sci (Lond). 2002 May;102(5):523-9. PubMed 11980571 ↗
  • DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-23. doi: 10.1152/ajpendo.1979.237.3.E214. PubMed 382871 ↗
  • Taubel J, Ferber G, Lorch U, Batchvarov V, Savelieva I, Camm AJ. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Br J Clin Pharmacol. 2014 Jan;77(1):170-9. doi: 10.1111/bcp.12168. PubMed 23713767 ↗
  • Taubel J, Lorch U, Ferber G, Singh J, Batchvarov VN, Savelieva I, Camm AJ. Insulin at normal physiological levels does not prolong QT(c) interval in thorough QT studies performed in healthy volunteers. Br J Clin Pharmacol. 2013 Feb;75(2):392-403. doi: 10.1111/j.1365-2125.2012.04376.x. PubMed 22775199 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2012
First posted
Jul 17, 2012
Start
Jul 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Aug 20, 2014
Last update
Aug 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01642485
Lead sponsor
Richmond Pharmacology Limited
Responsible party
Sponsor
First posted
Jul 17, 2012
Start date
Jul 2011
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Aug 20, 2014
Last update
Aug 20, 2014

Study contacts

Ulrike Lorch, MD FRCA FFPM
principal investigator · Richmond Pharmacology Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion